MIAMI BEACH, FLA.—The 4-year results of the SYNTAX trial presented by Ted Feldman, MD, indicate that revascularization with DES (Taxus, Boston Scientific) in patients with left main disease show ...
NEW YORK—Fresh results from the SYNTAX trial show that patients undergoing revascularization for unprotected left main disease receive comparable angina relief from either coronary artery bypass ...
NATICK, Mass. and WASHINGTON, Oct. 14 BostonScientific Corporation (NYSE: BSX) today announced 12-month left main andthree-vessel disease subset data from its landmark SYNTAX trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback